Agenda at a Glance
Summit Day 1 - 14/9
Summit Day 2 - 15/9
Summit Day 3 - 16/9
Summit Day 4 - 17/9
Industry Leader’s Fireside Chat
Late Breaking Abstracts
Late Breaking Abstracts
Keynote Presentations from FDA & Novartis
Virtual Speed Networking
DISCOVERY
TRANSLATION
CLINICAL MANAGEMENT
MANUFACTURING
Developing Safe,
Controllable CAR-TCR
Products
Achieving Optimal Cell Fitness
Setting Up Effective Infrastructure to Support Trials
Disruptive Innovation in Cell Therapy Analytics
Refreshment Break & Tech Slam
Innovative Target Identification to Define Clinically Beneficial and Safe Targets
Translational Experience with Allogeneic CAR and TCR Therapy
Managing Growth Strain on Clinical Settings
Scaling-Up for Late Stage Trials and Commercial Capacity
Refreshment Break & Apheresis Panel Discussion
Refreshment Break & Diversity in CAR-TCR Panel Discussion
Refreshment Break & Poster Session
Refreshment Break & Virtual Speed Networking
Novel Construct Design to Tackle the Solid Tumor Microenvironment
Benchmark Clinical Biomarkers to Determine Safety and Efficacy
Running CAR-TCR Clinical Trials during a Pandemic
Facility Design to Enable Scale Up and Flexibility in Demand
Next Generation Gene Engineering Approaches for Enhanced Specificity
Strategies to Manage and Prevent Toxicity
Improving Accessibility for Patients Globally
CMC and Quality Control to Develop Robust, Reproducible Therapeutic Products